Loncastuximab tesirine Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Loncastuximab tesirine Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
37
Registered trials
59
Result records
6
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Loncastuximab tesirine can convert its Antibody drug conjugate (ADC) profile and CD19 x DNA biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Loncastuximab tesirine (query alias: loncastuximab tesirine) |
|---|---|
| Modality / target | Antibody drug conjugate (ADC); CD19 x DNA; CD19 inhibitors, DNA inhibitors |
| Highest global status | Approved |
| Originator | ADC Therapeutics SA |
| Active developers | Tanabe Pharma Corp., ADC Therapeutics SA, Swedish Orphan Biovitrum Pty Ltd. |
The MCP disease footprint includes B-cell lymphoma recurrent, B-cell lymphoma refractory, Diffuse large B-cell lymphoma recurrent. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07197307 | Phase 2 | Not yet recruiting | 120 | Best overall response rate (BORR) |
| NCT06919939 | Phase 2 | Recruiting | 26 | Number of Participants Experiencing Cytokine Release Syndrome (CRS)-related Toxicity after Epcoritamab Administration |
| NCT07573436 | Phase 1/2 | Not yet recruiting | 23 | Phase I: Define Maximum Tolerated Dose (MTD) based on the rate of dose-limiting toxicities (DLTs) during the DLT evaluation period. |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Risk stratification using total metabolic tumor volume in patients with relapsed/refractory follicular lymphoma treated with loncastuximab tesirine and rituximab
Phase 2; n=39; evaluation: Positive. Reported fields: CMR(EOT) = 77.0 %
INTEGRATED MOLECULAR AND METABOLIC PROFILING IDENTIFIES DETERMINANTS OF OUTCOME WITH LONCASTUXIMAB TESIRINE IN RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA
Not Applicable; n=41; evaluation: Positive. Reported fields: CR = 17.1 %
LARGE B-CELL LYMPHOMA TREATMENT WITH LONCASTUXIMAB TESIRINE IN AN ITALIAN REAL-LIFE EXPERIENCE
Not Applicable; n=37; evaluation: Positive. Reported fields: mOS = 5.5 Month
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Loncastuximab tesirine addresses B-cell lymphoma recurrent, B-cell lymphoma refractory, Diffuse large B-cell lymphoma recurrent. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Antibody drug conjugate (ADC)—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 6 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2022-07-12 | OEP Enters into a Strategic Partnership with Overland ADCT BioPharma to Address the Unmet Needs of Lymphoma Patients in Taiwan and Singapore | Approved | Financial terms not disclosed |
| 2022-07-08 | Sobi to license loncastuximab tesirine from ADC Therapeutics | Approved | US$55.0M upfront; US$380.0M milestones |
| 2022-01-18 | ADC Therapeutics has entered an exclusive license agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of ZYNLONTA in Japan | Approved | US$30.0M upfront; US$205.0M milestones |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- CLDN18.2 assay, cutoff, and intratumoral heterogeneity
- Payload-related toxicity and dose intensity
- Crowding from antibodies, bispecifics, CAR-Ts, and competing ADCs
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
